Kura Oncology Announces Commencement of Public Offering of Common Stock
05 mai 2020 16h01 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2020 Financial Results
04 mai 2020 16h05 HE
|
Kura Oncology, Inc.
– Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML – – Three abstracts accepted for presentation at ASCO, including mature...